Galderma prices IPO at CHF 53 per share and will start trading on the SIX Swiss Exchange tomorrow Press release
Galderma @ AAD 2024: new data demonstrate the long-term efficacy of nemolizumab in prurigo nodularis and its durability in atopic dermatitis Press release
Galderma announces record 2023 net sales of over 4 B USD and significant core EBITDA margin expansion Press release
Galderma to showcase latest updates from its broad, innovative and leading dermatology portfolio at the 2024 American Academy of Dermatology annual meeting Press release
Galderma announces regulatory filing acceptance for nemolizumab in prurigo nodularis and atopic dermatitis in the U.S. and EU Press release
Galderma launches ‘NEXT’, a ground-breaking trend report that unveils the future of aesthetics Press release
